Cargando…

Interferon β-1a subcutaneously 3 times/week clinical outcome in relapsing multiple sclerosis in Finland

Prognostic factors and long-term treatment response of interferon β-1a s.c tiw has not been studied in a real-life clinical cohort in Finland. The aim of the paper was to evaluate long-term treatment response, prognostic clinical factors and adherence among interferon β-1a s.c tiw treated patients i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Järvinen, Elina, Murtonen, Annukka, Tervomaa, Melina, Sumelahti, Marja-Liisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PAGEPress Publications, Pavia, Italy 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6908953/ https://www.ncbi.nlm.nih.gov/pubmed/31871598 http://dx.doi.org/10.4081/ni.2019.8177

Ejemplares similares

Increasing Incidence in Relapsing-Remitting MS and High Rates among Young Women in Finland: A Thirty-Year Follow-Up
por: Sumelahti, Marja-Liisa, et al.
Publicado: (2014)

Increased Female MS Incidence and Differences in Gender-Specific Risk in Medium- and High-Risk Regions in Finland from 1981–2010
por: Holmberg, Markus, et al.
Publicado: (2013)

Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis
por: Mankinen, Petri, et al.
Publicado: (2019)

Injectable Disease Modifying Agents in Multiple Sclerosis: Pattern of Medication Use and Clinical Effectiveness
por: Järvinen, Elina, et al.
Publicado: (2016)

Subcutaneous Interferon β-1a Administration by Electronic Auto-injector is Associated with High Adherence in Patients with Relapsing Remitting Multiple Sclerosis in a Real-life Study
por: Järvinen, Elina, et al.
Publicado: (2017)

Diffusion tensor imaging and disability progression in multiple sclerosis: A 4‐year follow‐up study
por: Kolasa, Marcin, et al.
Publicado: (2018)

My Migraine Voice survey: disease impact on healthcare resource utilization, personal and working life in Finland
por: Sumelahti, Marja-Liisa, et al.
Publicado: (2020)

Subcutaneous interferon β-1a three times weekly and the natural evolution of gadolinium-enhancing lesions into chronic black holes in relapsing and progressive multiple sclerosis: Analysis of PRISMS and SPECTRIMS trials
por: Traboulsee, A, et al.
Publicado: (2017)

Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing–remitting multiple sclerosis at year 1
por: Traboulsee, Anthony, et al.
Publicado: (2018)

Reasons for discontinuation of subcutaneous interferon β-1a three times a week among patients with multiple sclerosis: a real-world cohort study
por: Sabidó-Espin, Meritxell, et al.
Publicado: (2017)

Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis
por: Cohan, Stanley
Publicado: (2016)

Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study
por: Bar-Or, Amit, et al.
Publicado: (2018)

Tolerability of subcutaneous ofatumumab with long-term exposure in relapsing multiple sclerosis
por: Kramer, John, et al.
Publicado: (2023)

Monitoring interferon β treatment response with magnetic resonance spectroscopy in relapsing remitting multiple sclerosis
por: Yetkin, Mehmet Fatih, et al.
Publicado: (2016)

Advances in the treatment of relapsing–remitting multiple sclerosis: the role of pegylated interferon β-1a
por: Furber, Kendra L, et al.
Publicado: (2017)

Medical students’ experience of emotions and success in neurological studies – What do they tell us?
por: Ansakorpi, Hanna, et al.
Publicado: (2017)

Subcutaneous Interferon β-1a May Protect against Cognitive Impairment in Patients with Relapsing–Remitting Multiple Sclerosis: 5-Year Follow-up of the COGIMUS Study
por: Patti, Francesco, et al.
Publicado: (2013)

Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial
por: Dwyer, Michael G., et al.
Publicado: (2015)

EDSS Change Relates to Physical HRQoL While Relapse Occurrence Relates to Overall HRQoL in Patients with Multiple Sclerosis Receiving Subcutaneous Interferon β-1a
por: Vickrey, Barbara G., et al.
Publicado: (2015)

Seasonal adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational GEPAT-SMART study
por: Deftereos, Spyros N., et al.
Publicado: (2018)

Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis
por: Cocco, Eleonora, et al.
Publicado: (2015)

The innovative development in interferon beta treatments of relapsing‐remitting multiple sclerosis
por: Madsen, Claus
Publicado: (2017)

Efficacy and safety of subcutaneous interferon-β-1a in patients with a first demyelinating event and early multiple sclerosis
por: Freedman, Mark S
Publicado: (2014)

Profiling of Canonical and Non-Traditional Cytokine Levels in Interferon-β-Treated Relapsing–Remitting-Multiple Sclerosis Patients
por: D’Angelo, Chiara, et al.
Publicado: (2018)

Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis
por: Paolicelli, Damiano, et al.
Publicado: (2009)

Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis
por: Jankovic, Slobodan M
Publicado: (2010)

Approved Beta Interferons in Relapsing-Remitting Multiple Sclerosis: Is There an Odd One Out?
por: Clapin, Alexis
Publicado: (2012)

The Assessment for Disinvestment of Intramuscular Interferon Beta for Relapsing-Remitting Multiple Sclerosis in Brazil
por: Lemos, Livia Lovato Pires de, et al.
Publicado: (2017)

Oral contraceptives combined with interferon β in multiple sclerosis
por: Pozzilli, Carlo, et al.
Publicado: (2015)

Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study
por: Sánchez-de la Rosa, Rainel, et al.
Publicado: (2015)

Domestically Acquired Campylobacter Infections in Finland
por: Vierikko, Antti, et al.
Publicado: (2004)

Patient assessment of an electronic device for subcutaneous self-injection of interferon β-1a for multiple sclerosis: an observational study in the UK and Ireland
por: D’Arcy, Caroline, et al.
Publicado: (2012)

Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX study
por: Freedman, Mark S., et al.
Publicado: (2014)

Atorvastatin added to interferon beta for relapsing multiple sclerosis: a randomized controlled trial
por: Kamm, Christian Philipp, et al.
Publicado: (2012)

Adherence to self-administering interferon-β1a using RebiSmart® device in Mexican patients with relapsing multiple sclerosis
por: Sauri-Suárez, Sergio, et al.
Publicado: (2020)

Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart(®) in patients with multiple sclerosis
por: Edo Solsona, María Dolores, et al.
Publicado: (2017)

Outcomes of COVID-19 among patients treated with subcutaneous interferon beta-1a for multiple sclerosis
por: Freedman, Mark S., et al.
Publicado: (2021)

Clinical testing for neutralizing antibodies to interferon-β in multiple sclerosis
por: Creeke, Paul I., et al.
Publicado: (2013)

Subjective patient-reported versus objective adherence to subcutaneous interferon β-1a in multiple sclerosis using RebiSmart®: the CORE study
por: Zecca, Chiara, et al.
Publicado: (2017)

Stroke and cardiovascular risk factors among working-aged Finnish migraineurs
por: Sumelahti, Marja-Liisa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ca3qvs838o1tqblj146iajqvl7